NIH backs down from IP grab
02 August, 2002 by Melissa TrudingerThe US National Institutes of Health will defer implementing a policy that would allow it to limit ownership of patent rights and IP developed by NIH-funded Australian researchers.
de Kretser returns as Monash IR&D director
02 August, 2002 by Tanya HollisReproductive biologist Prof David de Kretser has returned to the director's role at the Monash Institute of Reproduction and Development.
AusBiotech gears up for conference
01 August, 2002 by Tanya HollisPeak industry organisation AusBiotech said it had secured 600 registrations so far to a conference it hopes to make an Australian biotechnology industry institution.
Perth PDF moves to become a biotech
31 July, 2002 by Pete YoungOne of Australia's oldest pooled development funds wants to toss in the towel as an investment vehicle to merge with its most promising holding, Perth biomed Clinical Cell Culture (C3).
More kudos for Cory
30 July, 2002 by Tanya HollisWalter and Eliza Hall Institute director Prof Suzanne Cory has been awarded a Royal Society medal in recognition of her work into the molecular basis for cancer.
Market forces: do biotechs list too early?
26 July, 2002 by Georgina DunnWhat's the difference between a biotech and a dot com? The average age of the board or directors. Funny? Maybe, but not exactly accurate. While there may be a sense of déjà vu - small start-ups looking for cash stampeding to the market - the biotech industry, unlike dot coms, is anything but an overnight phenomenon.
Mass spectrometry: the supply side
26 July, 2002 by Iain ScottIn the last 10 years, we've seen a dizzying array of new variations of mass spectrometry instruments, and at the same time as we've seen radical changes in scientific discovery. Mass spectrometry has become a key tool across the life sciences, from discovery to routine lab work. Consequently there seems to be an almost limitless range of permutations of mass spec.
Where have all the young minds gone?
24 July, 2002 by Melissa TrudingerThe decision to pursue post-doctoral studies overseas is one of the defining moments in a young Australian scientist's career.
Biotechs missing out on tax perk: E&Y
23 July, 2002 by Tanya HollisSmall to medium-sized biotechnology companies are missing out on an important source of cash by failing to claim the Federal R&D rebate, according to a tax specialist.
Science award nominations closing Friday
22 July, 2002 by Iain ScottNominations for two major Australian science prizes, the Clunies Ross Award and the Unsung Hero of Australian Science, close this Friday.
UTS team takes research to the world
22 July, 2002 by Melissa TrudingerA team of scientists and university administrators from the University of Technology, Sydney, has returned from a world tour that established new contacts and showcased the University's research activities.
Perth-based biotech aims for Singapore listing
22 July, 2002 by Pete YoungPerth life science company Rockeby Biomed is expanding in several directions simultaneously.
Bio conference success: it's all in the planning
17 July, 2002 by Melissa TrudingerA post-Bio 2002 debriefing session organised by AusBiotech and the BioMelbourne Network this week had one big message for future delegations - planning, planning, planning.
Diatranz denies trans-Tasman plans
17 July, 2002 by Tanya HollisA New Zealand company working on a pig-derived cure for type 1 diabetes has denied reports of a planned move to Australia.
Red tape hampering Sirtex at home
17 July, 2002 by Pete YoungThe US is embracing Sirtex Medical's novel anti-cancer technology more quickly than Australia where government evaluation of the technology appears to have stalled.
